A detailed history of Cutler Group LP transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Cutler Group LP holds 1,000 shares of AMLX stock, worth $4,960. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,000
Previous 900 11.11%
Holding current value
$4,960
Previous $13,000 84.62%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 19, 2024

BUY
$2.71 - $19.57 $271 - $1,957
100 Added 11.11%
1,000 $2,000
Q4 2023

Jan 18, 2024

BUY
$12.07 - $18.46 $10,259 - $15,691
850 Added 1700.0%
900 $13,000
Q3 2023

Nov 07, 2023

BUY
$18.08 - $23.45 $903 - $1,172
50 New
50 $0
Q4 2022

Feb 07, 2023

SELL
$29.75 - $39.26 $247,668 - $326,839
-8,325 Reduced 72.23%
3,200 $118,000
Q3 2022

Oct 25, 2022

BUY
$17.15 - $30.92 $65,410 - $117,928
3,814 Added 49.46%
11,525 $324,000
Q2 2022

Aug 04, 2022

BUY
$6.85 - $19.93 $52,820 - $153,680
7,711 New
7,711 $148,000

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $290M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Cutler Group LP Portfolio

Follow Cutler Group LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.